Core Insights - Teleflex Incorporated announced findings from a multinational study demonstrating the efficacy of Arrow™ Chlorhexidine-Impregnated Central Venous Catheters (CVCs) in reducing central line-associated bloodstream infections (CLABSIs) by 70.5% [2][3][4] Study Findings - The study involved over 6,670 patients from 12 Intensive Care Units across eight countries, including India, Malaysia, Papua New Guinea, Colombia, Egypt, and Turkey [1] - Patients using chlorhexidine-impregnated CVCs had a significantly lower incidence of infections caused by various pathogens, including gram-negative and gram-positive bacteria, as well as fungi [4][7] - The study highlighted that unprotected CVCs may pose an independent risk factor for CLABSI compared to chlorhexidine-impregnated CVCs, even with adherence to best practices [3][7] Implications for Teleflex - The results reinforce Teleflex's claims regarding the effectiveness of its Arrowg+ard Blue™ and Arrowg+ard Blue Plus™ CVCs against common CLABSI pathogens [4] - The company aims to enhance healthcare quality through innovative medical technologies, positioning itself as a trusted partner in the healthcare sector [5][6]

Core Insights - Teleflex Incorporated has launched two initiatives to raise awareness about benign prostatic hyperplasia (BPH) during Men's Health Month, focusing on quality-of-life issues and potential rectal toxicity from prostate cancer radiation treatment [3][8]. Group 1: Awareness Initiatives - The initiatives include the "Prostate Monster" ad campaign and the Prostate Education Express, a mobile training center that will tour major U.S. cities throughout 2025 [4][5]. - The Prostate Education Express aims to educate both physicians and the community about BPH and the benefits of the UroLift™ System and Barrigel™ rectal spacer [4][7]. Group 2: UroLift™ System - The UroLift™ System is a minimally invasive treatment for BPH symptoms, indicated for men aged 45 and older, and has been used to treat over 500,000 men globally [10][6]. - A clinical study showed a low retreatment rate of about 2-3% per year, indicating the durability of the UroLift™ System [10]. Group 3: Barrigel™ Rectal Spacer - Barrigel™ rectal spacer is the first hyaluronic acid rectal spacer designed to protect the rectum during radiation therapy for prostate cancer, with over 50,000 men treated [12][8]. - A clinical study found that 98.5% of men treated with Barrigel™ achieved at least a 25% reduction in radiation to the rectum, with an average reduction of 85% [8].

Core Insights - Teleflex Incorporated has published its 2024 Global Impact Report, highlighting its achievements and future goals in Corporate Social Responsibility (CSR) [1][2] - The report aligns with major sustainability frameworks including the Global Reporting Initiative (GRI), Sustainability Accounting Standards Board (SASB), and Taskforce on Climate-Related Financial Disclosures (TCFD) [1] CSR Pillars - The 2024 Global Impact Report details accomplishments and future plans across four CSR pillars: Community & Sustainable Healthcare, Planet & Environment, People, and Ethics & Governance [2] Key Highlights - The report showcases Teleflex's ongoing commitment to CSR and the recognition it has gained among stakeholders, reflecting the pride of employees in the company's impact on the planet and society [2] - Teleflex has conducted a double materiality assessment in line with the E.U. Corporate Sustainability Reporting Directive to ensure its CSR strategy remains relevant [7] - The company has committed to the World Economic Forum Zero Health Gaps Pledge, aiming for equitable access to healthcare [7] - In 2024, Teleflex achieved ISO 14001 certification for 6 sites and plans to expand this certification in the future [7]

Two Head-to-Head Randomized Trials Highlight Superior Early Patient Experience with the UroLift™ System for BPH1-2 First-Ever Analysis Utilizing the American Urological Association Quality Registry (AQUA) to Assess BPH Treatment Modalities Shows Strongest Symptom Improvement Score Shift with UroLift™ System at Three Months.3 First Study to Confirm Safety of Stabilized Hyaluronic Acid (sHA) Rectal Spacer in Cases with Rectal Wall Infiltration (RWI).4 WAYNE, Pa., May 15, 2025 (GLOBE NEWSWIRE) -- Teleflex Inc ...

Teleflex (TFX) 2025 Conference May 14, 2025 04:40 PM ET Speaker0 My name is Craig Bijou, one of the med tech analysts here at BofA. And it's a pleasure to have Teleflex here from the company, Liam Kelly, CEO and Larry Koosh, vice president investor relations and strategy development. Thank you guys for coming. Speaker1 Thanks for having us. Maybe Speaker0 just want to start with, let's start with Q1 results. You're a couple of weeks removed from that. Just talk about, I guess, some of the, I I guess, how Q1 ...

Data also demonstrate significantly lower rates of postoperative reflux and decreased incidence of de novo gastroesophageal reflux disease (GERD) without affecting total weight loss at 1-year*, and shorter average hospital length of stay (LOS) associated with use of the Titan SGS™ Stapler compared with multi-fire staplers1 WAYNE, Pa., May 13, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the publication of a new retrospective a ...

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Teleflex Incorporated due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation Details - The investigation is prompted by a significant drop in Teleflex's stock price, which fell by 21.6% on February 27, 2025, following the announcement of a company split and a €760 million deal with Biotronik [3]. - Shareholders who purchased Teleflex securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in recovering hundreds of millions for investors [4]. - The firm has been recognized for its leadership in securities class action settlements, achieving the largest settlement against a Chinese company at the time and ranking highly in the number of settlements since 2013 [4].

NEW YORK, May 1, 2025 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Teleflex Incorporated (NYSE: TFX) resulting from allegations that Teleflex may have issued materially misleading business information to the investing public.So What: If you purchased Teleflex securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. Th ...

LOS ANGELES, May 1, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Teleflex Incorporated ("Teleflex" or "the Company") (NYSE: TFX) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Teleflex is the subject of an article published by Fierce Biotech on February 27 ...

For the quarter ended March 2025, Teleflex (TFX) reported revenue of $700.67 million, down 5% over the same period last year. EPS came in at $2.91, compared to $3.21 in the year-ago quarter.The reported revenue represents a surprise of +0.22% over the Zacks Consensus Estimate of $699.13 million. With the consensus EPS estimate being $2.88, the EPS surprise was +1.04%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expect ...